Idacio (Adalimumab-Aacf)

$807.87$3,533.17

Idacio (adalimumab-aacf) is a prescription medicine indicated for the treatment of multiple conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, juvenile idiopathic arthritis, ankylosing spondylitis, and plaque psoriasis1.

Idacio is approved by the FDA in the USA, as well as by the EMA in the EU2,3.

SKU: N/A Categories: ,

What is Idacio (adalimumab-aacf) for?

Idacio (adalimumab-aacf) is an adalimumab biosimilar medicine. It’s prescribed for the treatment of: Rheumatoid arthritis Juvenile idiopathic arthritis Psoriatic arthritis Ankylosing spondylitis Crohn’s disease Ulcerative colitis Plaque psoriasis[1].

Idacio is administered as a subcutaneous injection and is available in a 40 mg/ 0.8 mL presentation[4].

How does Idacio (adalimumab-aacf) work?

Idacio’s active ingredient, adalimumab, is a monoclonal antibody. It targets and binds to the tumour necrosis factor (TNF) in the body. TNF is considered to cause the inflammations experienced by patients with the diseases Idacio aims to treat. When adalimumab binds with TNF, it blocks its activity. As a result, it reduces inflammation and alleviates other symptoms of the diseases[3].

Where has Idacio-(adalimumab-aacf) been approved?

Idacio-(adalimumab-aacf) is currently approved in:

  • USA[2]
  • EU [3]
  • Australia[5]
  • Canada[6].
Package

Single pre-filled syringe x 40 mg/0.8 mL, Two pre-filled syringe x 40 mg/0.8 mL, Six pre-filled syringe x 40 mg/0.8 mL